Related Experiment Videos
Oral acyclovir and herpes labialis: a randomized, double-blind, placebo-controlled study
Journal of the American Dental Association (1939)
|July 1, 1987
Summary
Oral acyclovir (200 mg) demonstrated a significant antiviral effect in patients with herpes labialis. While effective, higher doses or a loading dose may enhance treatment outcomes for this common viral infection.
Area of Science:
- Virology
- Dermatology
- Pharmacology
Background:
- Herpes labialis, commonly known as cold sores, is a prevalent viral infection.
- Recurrent episodes of herpes labialis can cause significant discomfort and impact quality of life.
Purpose of the Study:
- To evaluate the clinical efficacy of oral acyclovir in managing herpes labialis.
- To assess the impact of acyclovir on key clinical parameters of herpes labialis lesions.
Main Methods:
- A randomized, placebo-controlled study involving 210 patients with culture-confirmed herpes labialis.
- Patients received oral acyclovir (200 mg, five times daily for 5 days) or a placebo.
- Clinical parameters including lesion crust loss and size reduction were monitored from day 1 to day 5 over three episodes.
Main Results:
- Acyclovir treatment resulted in a significant antiviral effect compared to placebo.
- Favorable effects were observed on lesion crust loss and size reduction.
- The study identified potential for improved efficacy with adjusted dosing regimens.
Conclusions:
- Oral acyclovir shows a beneficial effect in treating herpes labialis.
- Higher dosages or the incorporation of a loading dose may further enhance acyclovir's efficacy for herpes labialis.
- Further research into optimized acyclovir dosing is warranted.